The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes
de Lordes Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Canguçu V
Diabetes care · 94 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 1998-05-01 · Diabetes Care · vol. 21 · número 5 · págs. 682–686
- Editorial
- American Diabetes Association
- Citado
- 196 citas · más que el 96% de estudios similares · 5.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 4 trabajos
- Acceso
- De pago
- Áreas de investigación
- Magnesium in Health and Disease · Magnesium Alloys: Properties and Applications · Magnesium Oxide Properties and Applications
- Palabras clave
- type 2 diabetes, magnesium supplementation, magnesium oxide, hypomagnesemia, glycemic control, intracellular magnesium, plasma magnesium, urinary magnesium excretion, peripheral neuropathy, coronary disease, insulin resistance, HbA1c, fructosamine, mononuclear cells, dose-response relationship, oral antidiabetic drugs, dietary therapy, monotherapy versus combination therapy
- MeSH
- humans, diabetes mellitus, type 2, hyperglycemia, body weight, magnesium, fructosamine, blood glucose, glucose tolerance test, body mass index, fasting, double-blind method, dose-response relationship, drug, reference values, dietary supplements, adult, aged, middle aged, female, male, glycated hemoglobin
6 autores
- Maria de Lourdes Lima🇧🇷Universidade Federal da Bahia
- Thomaz Cruz🇧🇷Universidade Federal da Bahia
- Judith Carreiro Pousada🇧🇷Universidade Federal da Bahia
- Luiz Erlon Araújo Rodrigues🇧🇷Universidade Federal da Bahia
- Karyne Freitas Barbosa🇧🇷Universidade Federal da Bahia
- Valquiria Canguçu🇧🇷Universidade Federal da Bahia
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Hypomagnesemia occurs in 25-38% of patients with type 2 diabetes. Several studies have suggested an association between magnesium (Mg) depletion and insulin resistance and/or reduction of insulin secretion in these cases. Our purpose was to evaluate if Mg supplementation (as magnesium oxide [MgO]) would improve metabolic control in patients with type 2 diabetes.
Research design and methods
We studied 128 patients with type 2 diabetes (32 men, 96 women, aged 30-69 years), treated by diet or diet plus oral antidiabetic drugs, in the Bahia Federal University Hospital, Brazil. Patients at risk for hypomagnesemia or with reduced renal function were excluded. This study was a clinical randomized double-blind placebo-controlled trial. Patients received either placebo, 20.7 mmol MgO, or 41.4 mmol MgO daily (elementary Mg) for 30 days. Mg concentrations were measured in plasma, in mononuclear cells, and in 24-h urine samples. Fasting blood glucose, HbA1, and fructosamine were used as parameters of metabolic control.
Results
Of the patients, 47.7% had low plasma Mg, and 31.1% had low intramononuclear Mg levels. Intracellular Mg in patients with diabetes was significantly lower than in the normal population (62 blood donors; 1.4 +/- 0.6 vs. 1.7 +/- 0.6 micrograms/mg of total proteins). No correlation was found between plasma and intracellular Mg concentrations (r = -0.179; P = 0.15) or between Mg concentrations and glycemic control (r = -0.165; P = 0.12). Intracellular Mg levels were lower in patients with peripheral neuropathy than in those without (1.2 +/- 0.5 vs. 1.5 +/- 0.6 micrograms/mg). Similar findings were observed in patients with coronary disease (1.0 +/- 0.5 vs. 1.5 +/- 0.6 micrograms/mg). In the placebo and in the 20.7 mmol Mg groups, neither a change in plasma and intracellular levels nor an improvement in glycemic control were observed. Replacement with 41.4 mmol Mg tended to increase plasma, cellular, and urine Mg and caused a significant fall (4.1 +/- 0.8 to 3.8 +/- 0.7 mmol/l) in fructosamine (normal, 1.87-2.87 mmol/l).
Conclusions
Mg depletion is common in poorly controlled patients with type 2 diabetes, especially in those with neuropathy or coronary disease. More prolonged use of Mg in doses that are higher than usual is needed to establish its routine or selective administration in patients with type 2 diabetes to improve control or prevent chronic complications.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.